3214 related articles for article (PubMed ID: 12217812)
21. B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity.
Selmayr M; Menzel H; Kremer JP; Thierfelder S; Mocikat R
Cancer Gene Ther; 2000 Mar; 7(3):501-6. PubMed ID: 10766357
[TBL] [Abstract][Full Text] [Related]
22. Somatically mutated regions of immunoglobulin on human B-cell lymphomas code for peptides that bind to autologous major histocompatibility complex class I, providing a potential target for cytotoxic T cells.
Gricks CS; Rawlings E; Foroni L; Madrigal JA; Amlot PL
Cancer Res; 2001 Jul; 61(13):5145-52. PubMed ID: 11431353
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
24. Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders.
Milosević DB
J Exp Clin Cancer Res; 2004 Mar; 23(1):9-13. PubMed ID: 15149145
[TBL] [Abstract][Full Text] [Related]
25. [Antitumor immune responses induced by idiotype-pulsed dendritic cells with cell-penetrating peptide vaccination in vivo].
Chang JH; Shi YX; Zhiang XS; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):804-7. PubMed ID: 18396634
[TBL] [Abstract][Full Text] [Related]
26. [Preparation of heat shock protein 70 (Hsp70) and idiotypic determinant single-chain antibody (Id-ScFv) in a patient with B-cell chronic lymphatic leukemia (B-CLL) and antitumor effect of peptide complex Hsp70-Id].
Ye Q; Wang ZH; Qin SK
Ai Zheng; 2008 Feb; 27(2):133-8. PubMed ID: 18279608
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
Pai Kasturi S; Qin H; Thomson KS; El-Bereir S; Cha SC; Neelapu S; Kwak LW; Roy K
J Control Release; 2006 Jul; 113(3):261-70. PubMed ID: 16793161
[TBL] [Abstract][Full Text] [Related]
28. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
[TBL] [Abstract][Full Text] [Related]
29. Immune responses to human tumors: development of tumor vaccines.
Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
[TBL] [Abstract][Full Text] [Related]
30. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
[TBL] [Abstract][Full Text] [Related]
31. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
Campbell MJ; Carroll W; Kon S; Thielemans K; Rothbard JB; Levy S; Levy R
J Immunol; 1987 Oct; 139(8):2825-33. PubMed ID: 3498771
[TBL] [Abstract][Full Text] [Related]
32. Genetically engineered dendritic cell-based cancer vaccines (review).
Bubeník J
Int J Oncol; 2001 Mar; 18(3):475-8. PubMed ID: 11179474
[TBL] [Abstract][Full Text] [Related]
33. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.
Chen TT; Tao MH; Levy R
J Immunol; 1994 Nov; 153(10):4775-87. PubMed ID: 7525715
[TBL] [Abstract][Full Text] [Related]
34. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity.
Mocikat R; Selmayr M; Thierfelder S; Lindhofer H
Cancer Res; 1997 Jun; 57(12):2346-9. PubMed ID: 9192805
[TBL] [Abstract][Full Text] [Related]
35. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
36. Vaccine Trials for the Clinician: Prospects for Tumor Antigens.
Osanto S
Oncologist; 1997; 2(5):284-299. PubMed ID: 10388061
[TBL] [Abstract][Full Text] [Related]
37. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
38. DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
Stevenson FK; Rice J; Ottensmeier CH; Thirdborough SM; Zhu D
Immunol Rev; 2004 Jun; 199():156-80. PubMed ID: 15233733
[TBL] [Abstract][Full Text] [Related]
39. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG
Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with membrane-associated idiotype provides greater and more prolonged protection of animals from tumor challenge than the soluble form of idiotype.
Ghosh SK; White LM; Ghosh R; Bankert RB
J Immunol; 1990 Jul; 145(1):365-70. PubMed ID: 1972719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]